Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD

Table 1 Baseline characteristics of the participants included in the analysis for the objective 1

	All subjects^¥ N = 306 (96.23%)
Age [years; M ± SD]	75.95 ± 3.43
Gender [female; n (%)]	192 (62.75%)
Education [high^§; n (%)]	211 (68.95%)
ACDI [M ± SD]	1.44 ± 2.92
HABC-M cognitive score (subject) [M ± SD]	3.32 ± 2.79
HABC-M cognitive score (informant) [M ± SD]	1.84 ± 2.21
MMSE [M ± SD]	28.67 ± 0.95
CDR [= 0; n (%)]	306 (100%)
FSCRT free recall [M ± SD]	30.15 ± 5.35
FSCRT total recall [M ± SD]	46.10 ± 1.97
FAB [M ± SD]	16.44 ± 1.66
TMT B-A [s; M ± SD]	47.81 ± 35.40
Lexical fluency [M ± SD]	22.46 ± 5.91
Semantic fluency [M ± SD]	31.44 ± 7.16
APOE [presence of ε4; n (%)]	60 (19.61%)
Amyloid load [¹⁸F-AV-45 SUVr; M ± SD]	0.78 ± 0.19
Brain glucose metabolism [¹⁸F-FDG SUV; M ± SD]	2.45 ± 0.25

ACDI Awareness of Cognitive Decline Index, HABC-M Healthy Aging Brain Care – Monitor, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, FCSRT Free and Cued Selective Reminding Test, FAB Frontal Assessment Battery, TMT Trail Making Test, ¹⁸F-AV-45 SUVr florbetapir standardized uptake value ratio (index of amyloid deposition), ¹⁸F-FDG SUV fluorodeoxyglucose standardized uptake value (metabolic index)
^¥Subjects included in the analysis were those with age, gender, educational level, ¹⁸F-AV-45 SUVr and ¹⁸F-FDG SUV available at baseline, and at least two timepoints for the ACDI
^§Equal to or higher than high-school diploma (≥ 12 years)

ISSN: 1758-9193